Furthermore, the efficacy of EGFR-targeted therapy appears to be associated with T-cell-mediated immune responses, suggesting that combining EGFR inhibitors or antibodies with ICIs could offer a promising therapeutic approach for BC patients with high EGFR copy numbers. This evidence concerns the gene EGFR and breast cancer.